Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pacira Pharm Inc (NQ: PCRX ) 14.19 +0.22 (+1.57%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,036,077 Open 14.02 Bid (Size) 13.65 (3) Ask (Size) 14.45 (1) Prev. Close 13.97 Today's Range 13.88 - 14.40 52wk Range 11.16 - 38.23 Shares Outstanding 44,454,792 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path August 12, 2024 Pacira BioSciences faces a significant setback as the U.S. District Court invalidates its key patent on Exparel, leading to a 40% stock drop. Exparel, crucial to Pacira's revenue, is now vulnerable,... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Where Pacira BioSciences Stands With Analysts August 12, 2024 Via Benzinga Performance YTD -55.66% -55.66% 1 Month -28.98% -28.98% 3 Month -53.20% -53.20% 6 Month -52.65% -52.65% 1 Year -62.04% -62.04% More News Read More JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session August 12, 2024 Via Benzinga Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey August 09, 2024 From Pacira BioSciences Via GlobeNewswire Expert Ratings For Pacira BioSciences July 25, 2024 Via Benzinga NASDAQ:PCRX: good value for what you're paying. June 26, 2024 Via Chartmill NASDAQ:PCRX, an undervalued stock with good fundamentals. June 05, 2024 Via Chartmill Analyst Ratings For Pacira BioSciences May 08, 2024 Via Benzinga NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. August 08, 2024 Via Chartmill PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024 July 30, 2024 Via InvestorPlace Pacira BioSciences Reports Second Quarter 2024 Financial Results July 30, 2024 From Pacira BioSciences Via GlobeNewswire 3 Biotech Stocks to Buy on the Dip: July 2024 July 29, 2024 Via InvestorPlace Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024 July 23, 2024 From Pacira BioSciences Via GlobeNewswire In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals. July 17, 2024 Via Chartmill Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025 July 10, 2024 From Pacira BioSciences Via GlobeNewswire Top 5 Health Care Stocks That May Explode In July July 08, 2024 Via Benzinga This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday July 03, 2024 Via Benzinga Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights July 02, 2024 Via Benzinga Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference May 30, 2024 From Pacira BioSciences Via GlobeNewswire When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. May 15, 2024 Via Chartmill Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 May 10, 2024 From Pacira BioSciences Via GlobeNewswire Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes May 08, 2024 From Pacira BioSciences Via GlobeNewswire PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program May 07, 2024 From Pacira BioSciences Via GlobeNewswire Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference May 07, 2024 From Pacira BioSciences Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
